GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Gross Profit

GenMark Diagnostics (GenMark Diagnostics) Gross Profit : $67.9 Mil (TTM As of Dec. 2020)


View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Gross Profit?

GenMark Diagnostics's gross profit for the three months ended in Dec. 2020 was $19.4 Mil. GenMark Diagnostics's gross profit for the trailing twelve months (TTM) ended in Dec. 2020 was $67.9 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. GenMark Diagnostics's gross profit for the three months ended in Dec. 2020 was $19.4 Mil. GenMark Diagnostics's Revenue for the three months ended in Dec. 2020 was $50.1 Mil. Therefore, GenMark Diagnostics's Gross Margin % for the quarter that ended in Dec. 2020 was 38.73%.

GenMark Diagnostics had a gross margin of 38.73% for the quarter that ended in Dec. 2020 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of GenMark Diagnostics was 61.14%. The lowest was -23.90%. And the median was 41.37%.

Warning Sign:

GenMark Diagnostics Inc gross margin has been in long term decline. The average rate of decline per year is -11.7%.


GenMark Diagnostics Gross Profit Historical Data

The historical data trend for GenMark Diagnostics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics Gross Profit Chart

GenMark Diagnostics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.57 20.01 19.48 28.60 67.94

GenMark Diagnostics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.12 16.15 15.85 16.54 19.40

Competitive Comparison of GenMark Diagnostics's Gross Profit

For the Medical Devices subindustry, GenMark Diagnostics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMark Diagnostics's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's Gross Profit distribution charts can be found below:

* The bar in red indicates where GenMark Diagnostics's Gross Profit falls into.



GenMark Diagnostics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

GenMark Diagnostics's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as

Gross Profit (A: Dec. 2020 )=Revenue - Cost of Goods Sold
=171.554 - 103.61
=67.9

GenMark Diagnostics's Gross Profit for the quarter that ended in Dec. 2020 is calculated as

Gross Profit (Q: Dec. 2020 )=Revenue - Cost of Goods Sold
=50.08 - 30.682
=19.4

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $67.9 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

GenMark Diagnostics's Gross Margin % for the quarter that ended in Dec. 2020 is calculated as

Gross Margin % (Q: Dec. 2020 )=Gross Profit (Q: Dec. 2020 ) / Revenue (Q: Dec. 2020 )
=(Revenue - Cost of Goods Sold) / Revenue
=19.4 / 50.08
=38.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


GenMark Diagnostics  (NAS:GNMK) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

GenMark Diagnostics had a gross margin of 38.73% for the quarter that ended in Dec. 2020 => Competition eroding margins


GenMark Diagnostics Gross Profit Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


GenMark Diagnostics (GenMark Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
5964 La Place Court, Carlsbad, CA, USA, 92008-8829
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.
Executives
Tyler Jensen officer: SVP, Engineering and Tech Dev 5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw officer: VP, Assay Development 5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo officer: VP, Qual, Reg, & Clin Affairs 5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson officer: SVP, Corp. Accounts 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler officer: VP, Human Resources 5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins officer: SVP, Sales 5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director, officer: President & CEO 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier officer: SVP & General Counsel 5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell officer: SVP, Operations 5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff director DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox director 5964 LA PLACE COURT, CARLSBAD CA 92008